# Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma

> **NCT07738159** · PHASE2 · NOT_YET_RECRUITING · sponsor: **West China Hospital** · enrollment: 92 (estimated)

## Conditions studied

- Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
- QL1706
- Lenvatinib
- Chemotherapy

## Interventions

- **DRUG:** Iparomlimab and tuvonralimab injection (QL1706) + Lenvatinib + EP/EC
- **DRUG:** EP/EC

## Key facts

- **NCT ID:** NCT07738159
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2030-08-01
- **Final completion:** 2030-09-01
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2026-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07738159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07738159, "Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07738159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*